Year: 2024
Type: article
Abstract: As the most frequent primary hepatic malignancy and the third cause of cancer-related death, hepatocellular carcinoma (HCC) occurs primarily in cases of underlying chronic liver disease, being infection with hepatitis B and C the main cause. However, there are other relevant risk factors that contribute as well, such as non-alcoholic fatty liver disease (NAFLD) and its progressive subtype non-alcoholic steatohepatitis (NASH), obesity and diabetes among others. Currently there are several agents available for the systemic treatment of HCC and the guidelines support atezolizumab plus bevacizumab as the first-line therapy. However, some data show that non-viral HCC might benefit less from the treatment with immunotherapy. This article reviews the systemic treatment for advanced HCC focusing more on the results for non-viral causes.
Authors: Esther Una Cidon, Pilar Alonso Martinez
Institution: Royal Bournemouth Hospital
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4405854541